

**Flex Pharma Announces Positive Results
from Human Clinical Studies**

--First Clinical Proof-of-Concept--

August 11, 2014

Boston, MA – Flex Pharma, Inc., a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, announced today positive clinical results of its proprietary product for preventing muscle cramps. The Company expects to present the complete results at a future medical meeting.

The human studies consisted of two randomized, blinded, placebo-controlled crossover designs including a total of 40 enrolled subjects. The primary endpoint of each study was to evaluate the efficacy of the product in preventing muscle cramps. Each of the studies showed statistically significant results ($p < 0.0001$), demonstrating that the proprietary product reduced electrically induced muscle cramps in minutes, and its effect lasted for hours compared to untreated subjects.

“To our knowledge, no currently marketed products have been shown to have a beneficial effect on muscle cramping in randomized human clinical studies,” commented Flex Pharma Co-founder and Scientific Advisory Board Co-Chair, Rod MacKinnon M.D., who in 2003 won the Nobel Prize in Chemistry. “These study results mark an important step forward in our research and development and support our belief that our proprietary product has significant potential for creating a solution for people suffering from muscle cramping as a result of a broad range of neuromuscular disorders, such as multiple sclerosis, spinal spasticity, and cervical dystonia.”

“We are pleased to be partnering with leading academics in the effort to advance the science for treating and preventing muscle cramps related to neuromuscular disorders. With these positive results in healthy volunteers, we plan to initiate efficacy studies in patients with neuromuscular disorders in the first half of 2015,” stated Christoph Westphal, M.D., Ph.D., Chairman and Chief Executive Officer of Flex Pharma.

About Flex Pharma

Flex Pharma, Inc. is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders. Flex Pharma has demonstrated initial human efficacy related to muscle cramping in healthy volunteers. The Company plans to initiate efficacy studies in patients with neuromuscular disorders in the first half of 2015. Additional information about Flex Pharma is available online at <http://www.flex-pharma.com>.

Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate) and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer, Christoph Westphal, M.D., Ph.D. Flex Pharma is backed by the Longwood Fund, Bessemer Venture Partners, EcoR1 Capital and a number of additional blue chip institutional and angel investors.

Contact:

Elizabeth Woo
Corporate Communications & Investor Relations
Flex Pharma, Inc.
ewoo@flex-pharma.com
617-874-1829